Doxorubicin-enriched, ALDH<sup>br</sup> mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1
<p>Abstract</p> <p>Background</p> <p>The primary objective of this study was to test whether oncolytic herpes simplex virus type 1 (HSV1) could eradicate chemoresistant cancer stem cells (CSCs).</p> <p>Methods</p> <p>The fluorescent aldefluor rea...
Main Authors: | Zhuang Xiufen, Zhang Wen, Chen Yatong, Han Xiangping, Li Jie, Zhang Yu, Zhang Youhui, Zhang Shuren, Liu Binlei |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2407/12/549 |
Similar Items
-
Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
by: Yoshiaki Yura
Published: (2017-05-01) -
Oncolytic herpes simplex virus and immunotherapy
by: Wenqing Ma, et al.
Published: (2018-12-01) -
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells
by: Dhaval S. Sanchala, et al.
Published: (2017-05-01) -
Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells
by: Bonnie L. Hall, et al.
Published: (2020-11-01) -
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
by: Norah Aldrak, et al.
Published: (2021-06-01)